---
title: "Humacyte says FDA accepts IND for first-in-human CTEV CABG study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293928671.md"
description: "Humacyte announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human study of its coronary tissue-engineered vessel used in Coronary Artery Bypass Grafting (CABG). The Phase 2a trial is scheduled to begin this quarter, involving 10 adult patients. The study will assess primary patency at two months with follow-ups extending up to three years."
datetime: "2026-07-27T12:03:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293928671.md)
  - [en](https://longbridge.com/en/news/293928671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293928671.md)
generator: "portal-rs"
---

# Humacyte says FDA accepts IND for first-in-human CTEV CABG study

-   Humacyte secured FDA acceptance of its IND for a first-in-human study of its coronary tissue engineered vessel in CABG. \* Phase 2a trial set to start this quarter in 10 adult patients; primary patency check at two months, follow-up up to three years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9788296) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Humacyte CEO Laura Niklason to speak at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298590499.md)
- [Humacyte says FDA authorizes Symvess shelf life extension to 36 months](https://longbridge.com/en/news/298454743.md)
- [Heartflow highlights 2Q26 revenue up 48% YoY to $64.1 million in investor presentation](https://longbridge.com/en/news/298453843.md)
- [Surrozen submits FDA IND for SZN-8141 in diabetic macular edema](https://longbridge.com/en/news/298320376.md)
- [Prelude Therapeutics says FDA clears IND for PRT13722 in HR+/HER2- breast cancer](https://longbridge.com/en/news/298582497.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**